Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.O)

JAZZ.O on Nasdaq

152.05USD
25 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$152.05
Open
--
Day's High
--
Day's Low
--
Volume
5
Avg. Vol
562,245
52-wk High
$163.75
52-wk Low
$95.80

JAZZ.O

Chart for JAZZ.O

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $9,127.38
Shares Outstanding(Mil.): 60.03
Dividend: --
Yield (%): --

Financials

  JAZZ.O Industry Sector
P/E (TTM): 22.87 14.31 17.43
EPS (TTM): 6.65 -- --
ROI: 10.83 -7.26 -5.41
ROE: 22.79 -6.76 -4.69

BRIEF-Jazz Pharma to present key data on sleeping disorder drug at meeting

* Jazz pharmaceuticals to present phase 3 data on jzp-110, an investigational treatment for excessive sleepiness in patients with narcolepsy and with obstructive sleep apnea, during 31st annual sleep meeting Source text for Eikon: Further company coverage:

May 24 2017

BRIEF-Jazz pharmaceuticals announces Q1 2017 financial results

* Jazz pharmaceuticals announces first quarter 2017 financial results

May 09 2017

BRIEF-Jazz Pharmaceuticals announces positive results of JZP-110 study

* Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness

Apr 26 2017

BRIEF-Jazz Pharmaceuticals reports psoitive data from phase 2/3 study of Xyrem

* Jazz Pharmaceuticals announces positive results from the phase 2/3 express study of xyrem in pediatric patients with narcolepsy with cataplexy

Apr 24 2017

RPT-BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

Apr 06 2017

BRIEF-Hikma enters into settlement agreement with Jazz

* Enters into settlement agreement with Jazz for sodium oxybate

Apr 06 2017

BRIEF-Jazz Pharma settles Xyrem patent litigation with Hikma Pharma

* Jazz Pharmaceuticals reaches settlement with Hikma Pharmaceuticals related to Xyrem patent litigation

Apr 05 2017

BRIEF-Jazz Pharma says completes rolling submission of NDA for Vyxeos (CPX-351)

* Jazz pharmaceuticals completes rolling submission of new drug application for vyxeos™ (cpx-351), an investigational treatment for acute myeloid leukemia

Apr 03 2017

BRIEF-Jazz pharmaceuticals and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

* Jazz Pharmaceuticals Plc - co and Nippon Shinyaku enter into license agreements for development and commercialization of Defitelio and Vyxeos in Japan

Mar 30 2017

BRIEF-Jazz Pharmaceuticals announces positive results from phase 3 tones 3 and tones 4 studies of JZP-110

* Jazz pharmaceuticals announces positive results from the phase 3 tones 3 and tones 4 studies of jzp-110 in patients with obstructive sleep apnea Source text for Eikon: Further company coverage:

Mar 20 2017

More From Around the Web

Earnings vs. Estimates